Philadelphia, PA, United States of America

Liang-Chuan Wang

USPTO Granted Patents = 5 

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 51(Granted Patents)


Company Filing History:


Years Active: 2016-2024

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovations of Liang-Chuan Wang

Introduction

Liang-Chuan Wang is a prominent inventor based in Philadelphia, PA (US). He has made significant contributions to the field of biomedical research, particularly in the area of cancer treatment and immunotherapy. With a total of 5 patents, his work focuses on enhancing the efficacy of T cell therapies and targeting tumor microenvironments.

Latest Patents

One of his latest patents is titled "Inhibition of diacylglycerol kinase to augment adoptive T cell transfer." This invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoforms in a cell to enhance the cytolytic activity of the cell. In certain embodiments, the cells may be modified to express a chimeric antigen receptor (CAR). The inhibition of DGK in T cells used in adoptive T cell transfer increases the cytolytic activity of the T cells, which may be beneficial in treating various conditions, including cancer, infections, and immune disorders. Another notable patent is "Compositions and methods for targeting stromal cells for the treatment of cancer." This invention focuses on targeting the stromal cell population within a tumor microenvironment. It includes a composition that targets fibroblast activation protein (FAP) and features a chimeric antigen receptor (CAR) comprising an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.

Career Highlights

Liang-Chuan Wang has worked with esteemed institutions such as the University of Pennsylvania and The Wistar Institute of Anatomy & Biology. His research has significantly advanced the understanding of T cell functionality and cancer treatment strategies.

Collaborations

He has collaborated with notable colleagues, including Steven M. Albelda and Carl H. June, who are also recognized for their contributions to cancer research and immunotherapy.

Conclusion

Liang-Chuan Wang's innovative work in the field of immunotherapy and cancer treatment has the potential to transform therapeutic approaches and improve patient outcomes. His patents reflect a commitment to advancing medical science and addressing critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…